These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 9389378

  • 1. Effects of the CCK(A) receptor antagonists SR 27897B and PD140548 on baroreflex function in conscious rats.
    Bunting MW, Beart PM, Widdop RE.
    Eur J Pharmacol; 1997 Oct 15; 337(1):35-9. PubMed ID: 9389378
    [Abstract] [Full Text] [Related]

  • 2. Electrophysiological studies of the cholecystokininA receptor antagonists SR27897B and PD140548 in the rat isolated nodose ganglion.
    Beart PM, Krstew E, Widdop RE.
    Naunyn Schmiedebergs Arch Pharmacol; 1996 May 15; 353(6):693-7. PubMed ID: 8738304
    [Abstract] [Full Text] [Related]

  • 3. Opposite modulation of apomorphine- or amphetamine-induced stereotypy by antagonists of CCK receptors.
    Tieppo CA, Ferreira FS, Sassatani AS, Felicio LF, Nasello AG.
    Eur J Pharmacol; 2000 Jan 10; 387(2):189-96. PubMed ID: 10650159
    [Abstract] [Full Text] [Related]

  • 4. The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor.
    Gouldson P, Legoux P, Carillon C, Delpech B, Le Fur G, Ferrara P, Shire D.
    Eur J Pharmacol; 2000 Jul 21; 400(2-3):185-94. PubMed ID: 10988332
    [Abstract] [Full Text] [Related]

  • 5. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
    Boden PR, Higginbottom M, Hill DR, Horwell DC, Hughes J, Rees DC, Roberts E, Singh L, Suman-Chauhan N, Woodruff GN.
    J Med Chem; 1993 Mar 05; 36(5):552-65. PubMed ID: 7684452
    [Abstract] [Full Text] [Related]

  • 6. Contrasting roles of leu(356) in the human CCK(1) receptor for antagonist SR 27897 and agonist SR 146131 binding.
    Gouldson P, Legoux P, Carillon C, Delpech B, Le Fur G, Ferrara P, Shire D.
    Eur J Pharmacol; 1999 Nov 03; 383(3):339-46. PubMed ID: 10594328
    [Abstract] [Full Text] [Related]

  • 7. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
    Gully D, Fréhel D, Marcy C, Spinazzé A, Lespy L, Neliat G, Maffrand JP, Le Fur G.
    Eur J Pharmacol; 1993 Feb 23; 232(1):13-9. PubMed ID: 7681406
    [Abstract] [Full Text] [Related]

  • 8. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat.
    Matto V, Harro J, Allikmets L.
    Neuropharmacology; 1997 Mar 23; 36(3):389-96. PubMed ID: 9175618
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [3H]-SR 27897B: a selective probe for autoradiographic labelling of CCK-A receptors in the brain.
    Zajac JM, Gully D, Maffrand JP.
    J Recept Signal Transduct Res; 1996 Mar 23; 16(1-2):93-113. PubMed ID: 8771533
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Monitoring of tumour glucose metabolism by PET in a phase I study evaluating hormonal therapy in advanced pancreatic cancer.
    Eckel F, Lersch C, Lippl F, Schulte-Frohlinde E, Schusdziarra V, Helmberger H, Neverve J, Decker M, Frank R, Schwaiger M, Weber W.
    Scand J Gastroenterol; 2002 Aug 23; 37(8):972-7. PubMed ID: 12229975
    [Abstract] [Full Text] [Related]

  • 16. Pancreatic secretory response to feeding in the calf: CCK-A receptors, but not CCK-B/gastrin receptors are involved.
    Le Dréan G, Le Huërou-Luron I, Gestin M, Romé V, Bernard C, Chayvialle JA, Fourmy D, Guilloteau P.
    Can J Physiol Pharmacol; 2000 Oct 23; 78(10):813-9. PubMed ID: 11077982
    [Abstract] [Full Text] [Related]

  • 17. Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S.
    Gouldson P, Legoux P, Carillon C, Dumont X, Le Fur G, Ferrara P, Shire D.
    Eur J Pharmacol; 2000 Feb 18; 389(2-3):115-24. PubMed ID: 10688974
    [Abstract] [Full Text] [Related]

  • 18. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
    Bignon E, Bachy A, Boigegrain R, Brodin R, Cottineau M, Gully D, Herbert JM, Keane P, Labie C, Molimard JC, Olliero D, Oury-Donat F, Petereau C, Prabonnaud V, Rockstroh MP, Schaeffer P, Servant O, Thurneyssen O, Soubrié P, Pascal M, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1999 May 18; 289(2):742-51. PubMed ID: 10215648
    [Abstract] [Full Text] [Related]

  • 19. SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI.
    Shilling PD, Feifel D.
    Psychopharmacology (Berl); 2002 Nov 18; 164(3):285-93. PubMed ID: 12424552
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
    Fossa AA, DePasquale MJ, Morrone J, Zorn SH, Bryce D, Lowe JA, McLean S.
    J Pharmacol Exp Ther; 1997 Apr 18; 281(1):180-7. PubMed ID: 9103496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.